Dr. Patricia Beckmann is the Entrepreneurial Program Coordinator and Grant Administrator for AZBio supporting activities related to AZBio’s EDA Seed Fund Support Grant. Patricia’s overall career spans research, operations, law and venture capital.
M. Patricia Beckmann, PhD, Entrepreneurial Program and Grants
Patricia spent most of her career at Immunex Corporation (now Amgen) in Research, Administration and Law. She is co-inventor of the drug Enbrel for rheumatoid arthritis, psoriasis and psoriatic arthritis (peak sales ~$8B) and was awarded National Inventor of the Year in 2000 from the Intellectual Property Owner’s Association. She was an Investment Specialist at Microsoft co-founder Paul Allen’s Vulcan Capital (deploying over $120M in various investment vehicles) and a member of the original strategy team establishing the endowed Allen Institute for Brain Sciences in Seattle. She was also founding Chief Scientific Officer at proteomics and biomarker company Homestead Clinical (now Integrated Diagnostics), funded by the venture-backed Accelerator Corp. From 2008-2012 she was President of the state-funded Oregon Translational Research and Development Institute (OTRADI) where she developed an incubator model for university bioscience start-ups and received the prestigious Department of Commerce i6 Challenge Award for OTRADI. She founded the Life Science Washington Institute in 2017, an organization solely dedicated to fostering entrepreneur development.
Since 2012 Patricia has also been Managing Director of BioStrategy, LLC, a bioscience strategic and management consultancy. Through BioStrategy she helps university and entrepreneur-driven start ups, sometimes managing early-stage companies. In this capacity she has served as Chief Operating Officer (oncology and transplantation immunotherapy), a strategic advisor (dermatology and telemedicine) and CSO/CBO (biomarkers and proteomics), among others.
Patricia has served on the Boards of Cancer Research and Biostatistics, the Drug and Device Advisory Council of the Institute for Translational and Health Sciences at University of Washington, and the Advisory Board of Northwest Technology Ventures. She earned her PhD in biochemistry and pharmacology from the University of Arizona, College of Medicine, is a two-time Fulbright recipient (Sweden and India), an NRSA Fellow at the National Cancer Institute and was a Kauffman Fellow. She has over 50 peer-reviewed scientific publications and more than 40 issued U.S. Patents.